Jaguar Health Reports Preliminary Crofelemer Findings in Adult Short Bowel Syndrome Study
Four participants completed an ongoing open-label crofelemer pilot study, with reported changes in ostomy volume, parenteral-support volume and urinary output.
Jaguar Health, Inc. (Nasdaq:JAGX) and family company Napo Pharmaceuticals reported preliminary findings from an ongoing open-label pilot study of crofelemer in adults with Type 1 short bowel syndrome and intestinal failure. The results were presented on October 13, 2026 at the American College of Gastroenterology Annual Scientific Meeting.
The study is assessing liquid crofelemer in patients with Type 1 short bowel syndrome who were receiving stable parenteral support. Participants received 3 mg/kg/dose orally three times daily for 12 weeks.
The trial plans to enrol 6 subjects and is using reduction in ostomy volume as its primary endpoint. Four participants had completed the protocol when the results were reported.
Two subjects recorded lower ostomy volume after 12 weeks of treatment, with an average reduction of 5%. Three subjects experienced an average increase of 23% in ostomy output after crofelemer treatment ended.
One subject recorded a 9% reduction in parenteral-support volume at 12 weeks. Three subjects had improved urinary output at that point, with an average increase of 88%. The company said the urinary-output improvement remained in place at 4-weeks post cessation of oral crofelemer therapy.
No significant adverse events were observed in the subjects, and Napo said crofelemer was well tolerated. The pilot study remains ongoing.
Patients with intestinal failure, including people with short bowel syndrome and paediatric patients with microvillus inclusion disease, cannot absorb sufficient nutrients, electrolytes and fluids by mouth. They may therefore require total parenteral nutrition, with or without supplemental intravenous fluids, as part of parenteral support for up to seven days per week and up to 20+ hours per day.
The company said parenteral support is supportive and lifesaving but can be associated with serious, sometimes fatal complications. It also noted that patients with Type 1 short bowel syndrome, defined in the update as having less than 200 cm of small bowel length to ostomy, can experience high-volume ostomy output, electrolyte disturbances and reduced quality of life.
Napo said it remains focused on global development programmes for oral crofelemer in intestinal-failure patients receiving parenteral support, including patients with short bowel syndrome with intestinal failure and paediatric microvillus inclusion disease.
The company also referred to ongoing investigations of liquid oral crofelemer in paediatric intestinal-failure patients. It said patients receiving treatment orally for more than one year showed substantial reductions in weekly parenteral-support needs and in parenteral support normalised to body weight, with no significant clinical or laboratory abnormalities.
Napo is conducting a multicentre, randomised, double-blind, placebo-controlled Phase 2 clinical trial in adult Type 1 short bowel syndrome patients without colin-in-continuity. Jaguar said results are expected to be available early in the second half of 2027. The company described this timing as a prediction based largely on current expectations and projections and subject to risks, uncertainties and assumptions, some of which are beyond its control.
Jaguar said its intestinal-failure programme is expected to include a planned New Drug Application filing for crofelemer in microvillus inclusion disease in mid-2027. The company identified this expectation as a forward-looking statement and said it is subject to risks, uncertainties and assumptions.
Jaguar Health develops prescription drugs derived from plants for complicated gastrointestinal disease states. Its family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. are focused on crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure, including microvillus inclusion disease and short bowel syndrome.
Jaguar Health and Napo Pharmaceuticals reported preliminary findings from an ongoing open-label crofelemer study presented on October 13, 2026.
The study plans to enrol 6 subjects, with 4 participants having completed the protocol at the time of the update.
Reported findings included an average 5% reduction in ostomy volume for two subjects and an average 88% improvement in urinary output for three subjects.
One subject recorded a 9% reduction in parenteral-support volume, while three subjects had an average 23% increase in ostomy output after treatment stopped.
Jaguar said it expects a planned mid-2027 NDA filing for microvillus inclusion disease and expects Phase 2 results early in the second half of 2027; both statements are subject to stated uncertainties.
Jaguar Health said its family company Napo Pharmaceuticals had provided a recap of preliminary results presented on 13 October 2026 at the American College of Gastroenterology Annual Scientific Meeting for an ongoing open-label pilot study of crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome with intestinal failure. The study is ongoing.
The study is evaluating whether oral crofelemer reduces ostomy volume in adult patients with Type 1 short bowel syndrome with intestinal failure. The primary endpoint is reduction of ostomy volume.
Patients with Type 1 short bowel syndrome with intestinal failure who were on stable parenteral support received liquid crofelemer at 3 mg/kg/dose orally three times daily for 12 weeks. The ongoing study plans to enrol 6 subjects, and 4 participants had completed the protocol at the time of the update.
Jaguar Health reported that 2 subjects had decreased ostomy volume at 12 weeks of treatment by an average of 5%. It also reported that 3 subjects had increased ostomy output after crofelemer was stopped by an average of 23%.
Jaguar Health reported that 1 subject had a 9% decrease in parenteral-support volume at 12 weeks of treatment. Parenteral support comprises total parenteral nutrition with or without supplemental intravenous fluids.
Jaguar Health reported that 3 subjects had improved urinary output at 12 weeks by an average of 88%. The company said this improvement was sustained at 4-weeks post cessation of oral crofelemer therapy.
Jaguar Health reported that no significant adverse events were observed in any subjects and said crofelemer was well tolerated. The study remains an ongoing open-label pilot study.
Jaguar Health said patients with intestinal failure, including those with short bowel syndrome or paediatric patients with microvillus inclusion disease, cannot orally absorb adequate nutrients, electrolytes and fluids. They therefore require lifelong total parenteral nutrition with or without supplemental intravenous fluids, together comprising parenteral support, for up to seven days per week and up to 20+ hours per day; the company also said parenteral support is associated with serious, sometimes fatal complications.
Jaguar Health said Napo remains sharply focused on global development programmes for oral crofelemer therapy in intestinal-failure patients receiving parenteral support for rare diseases, including short bowel syndrome with intestinal failure and paediatric microvillus inclusion disease. The company also referred to ongoing investigations of liquid oral crofelemer formulations in paediatric patients.
Jaguar Health said results from ongoing investigations of liquid oral crofelemer formulations demonstrated substantial reductions in weekly parenteral-support needs and in parenteral support normalised to body weight in paediatric intestinal-failure patients dosed orally for more than one year. The company said there were no significant clinical or laboratory abnormalities.
Jaguar Health said Napo is conducting a multicentre, randomised, double-blind, placebo-controlled Phase 2 clinical trial in adult Type 1 short bowel syndrome patients without colin-in-continuity. The company said results are expected to be available early in the second half of 2027, describing its forward-looking statements as predictions based largely on current expectations and projections and subject to risks, uncertainties and assumptions, some of which are beyond its control.
Jaguar Health said its intestinal-failure programme is expected to include a planned New Drug Application filing for microvillus inclusion disease in mid-2027. The company identified this as a forward-looking expectation and said such statements are predictions subject to risks, uncertainties and assumptions, some of which are beyond its control.
Jaguar Health develops proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. Its family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on developing and commercialising crofelemer powder for oral solution for rare and orphan gastrointestinal disorders with intestinal failure, while Magdalena Biosciences is a joint venture focused on plant-derived prescription medicines for mental health indications.
Jaguar Health shares trade on Nasdaq under the ticker symbol JAGX.